We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Fennec Pharmaceuticals Inc | TSX:FRX | Toronto | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.22 | -1.72% | 12.58 | 12.37 | 12.82 | 12.61 | 12.61 | 12.61 | 602 | 22:00:00 |
Name of Nominee | Votes For | % Votes For | Votes Withheld | % Votes Withheld |
Dr. Khalid Islam | 9,766,926 | 92.47% | 795,329 | 7.53% |
Mr. Adrian Haigh | 9,767,181 | 92.47% | 795,074 | 7.53% |
Mr. Chris A. Rallis | 9,765,833 | 92.46% | 796,422 | 7.54% |
Mr. Marco Brughera | 10,558,689 | 99.97% | 3,566 | 0.03% |
Mr. Rostislav Raykov | 10,559,584 | 99.97% | 2,671 | 0.03% |
Shareholders voted 99.90% in favour of appointing Haskell & White LLP as auditors and authorizing the directors to fix the auditor remuneration, 97.46% in favour of the compensation paid to the Company’s named executive officers, and 92.27% in favour of the extension of certain outstanding options held by certain of the Company’s officers.
For further information, please contact:
Rosty Raykov Chief Executive Officer Fennec Pharmaceuticals Inc. T: (919) 636-5144
1 Year Fennec Pharmaceuticals Chart |
1 Month Fennec Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions